The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Biosimilars of Rituximab Market Research Report 2025
Synopsis
Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells.
The global Biosimilars of Rituximab market was valued at US$ 1774 million in 2023 and is anticipated to reach US$ 3184.6 million by 2030, witnessing a CAGR of 8.5% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Biosimilars of Rituximab, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilars of Rituximab.
Report Scope
The Biosimilars of Rituximab market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilars of Rituximab market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilars of Rituximab manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
AryoGen Pharmed
Biocad
Cadila Pharmaceuticals
Celltrion
Dr Reddy’s Laboratories
Teva
Hetero Group
Innovent Biologics
Intas Biopharmaceuticals
Viatris
Probiomed
TRPharma
Zenotech Laboratories
Segment by Type
500mg
100mg
Other
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Biosimilars of Rituximab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Biosimilars of Rituximab in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells.
The global Biosimilars of Rituximab market was valued at US$ 1774 million in 2023 and is anticipated to reach US$ 3184.6 million by 2030, witnessing a CAGR of 8.5% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Biosimilars of Rituximab, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilars of Rituximab.
Report Scope
The Biosimilars of Rituximab market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilars of Rituximab market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilars of Rituximab manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
AryoGen Pharmed
Biocad
Cadila Pharmaceuticals
Celltrion
Dr Reddy’s Laboratories
Teva
Hetero Group
Innovent Biologics
Intas Biopharmaceuticals
Viatris
Probiomed
TRPharma
Zenotech Laboratories
Segment by Type
500mg
100mg
Other
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Biosimilars of Rituximab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Biosimilars of Rituximab in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Biosimilars of Rituximab Market Overview
1.1 Product Overview and Scope of Biosimilars of Rituximab
1.2 Biosimilars of Rituximab Segment by Type
1.2.1 Global Biosimilars of Rituximab Market Value Comparison by Type (2024-2030)
1.2.2 500mg
1.2.3 100mg
1.2.4 Other
1.3 Biosimilars of Rituximab Segment by Application
1.3.1 Global Biosimilars of Rituximab Market Value by Application: (2024-2030)
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.4 Global Biosimilars of Rituximab Market Size Estimates and Forecasts
1.4.1 Global Biosimilars of Rituximab Revenue 2019-2030
1.4.2 Global Biosimilars of Rituximab Sales 2019-2030
1.4.3 Global Biosimilars of Rituximab Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Biosimilars of Rituximab Market Competition by Manufacturers
2.1 Global Biosimilars of Rituximab Sales Market Share by Manufacturers (2019-2024)
2.2 Global Biosimilars of Rituximab Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Biosimilars of Rituximab Average Price by Manufacturers (2019-2024)
2.4 Global Biosimilars of Rituximab Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Biosimilars of Rituximab, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Biosimilars of Rituximab, Product Type & Application
2.7 Biosimilars of Rituximab Market Competitive Situation and Trends
2.7.1 Biosimilars of Rituximab Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Biosimilars of Rituximab Players Market Share by Revenue
2.7.3 Global Biosimilars of Rituximab Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Biosimilars of Rituximab Retrospective Market Scenario by Region
3.1 Global Biosimilars of Rituximab Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Biosimilars of Rituximab Global Biosimilars of Rituximab Sales by Region: 2019-2030
3.2.1 Global Biosimilars of Rituximab Sales by Region: 2019-2024
3.2.2 Global Biosimilars of Rituximab Sales by Region: 2025-2030
3.3 Global Biosimilars of Rituximab Global Biosimilars of Rituximab Revenue by Region: 2019-2030
3.3.1 Global Biosimilars of Rituximab Revenue by Region: 2019-2024
3.3.2 Global Biosimilars of Rituximab Revenue by Region: 2025-2030
3.4 North America Biosimilars of Rituximab Market Facts & Figures by Country
3.4.1 North America Biosimilars of Rituximab Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Biosimilars of Rituximab Sales by Country (2019-2030)
3.4.3 North America Biosimilars of Rituximab Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Biosimilars of Rituximab Market Facts & Figures by Country
3.5.1 Europe Biosimilars of Rituximab Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Biosimilars of Rituximab Sales by Country (2019-2030)
3.5.3 Europe Biosimilars of Rituximab Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Biosimilars of Rituximab Market Facts & Figures by Country
3.6.1 Asia Pacific Biosimilars of Rituximab Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Biosimilars of Rituximab Sales by Country (2019-2030)
3.6.3 Asia Pacific Biosimilars of Rituximab Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Biosimilars of Rituximab Market Facts & Figures by Country
3.7.1 Latin America Biosimilars of Rituximab Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Biosimilars of Rituximab Sales by Country (2019-2030)
3.7.3 Latin America Biosimilars of Rituximab Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Biosimilars of Rituximab Market Facts & Figures by Country
3.8.1 Middle East and Africa Biosimilars of Rituximab Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Biosimilars of Rituximab Sales by Country (2019-2030)
3.8.3 Middle East and Africa Biosimilars of Rituximab Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Biosimilars of Rituximab Sales by Type (2019-2030)
4.1.1 Global Biosimilars of Rituximab Sales by Type (2019-2024)
4.1.2 Global Biosimilars of Rituximab Sales by Type (2025-2030)
4.1.3 Global Biosimilars of Rituximab Sales Market Share by Type (2019-2030)
4.2 Global Biosimilars of Rituximab Revenue by Type (2019-2030)
4.2.1 Global Biosimilars of Rituximab Revenue by Type (2019-2024)
4.2.2 Global Biosimilars of Rituximab Revenue by Type (2025-2030)
4.2.3 Global Biosimilars of Rituximab Revenue Market Share by Type (2019-2030)
4.3 Global Biosimilars of Rituximab Price by Type (2019-2030)
5 Segment by Application
5.1 Global Biosimilars of Rituximab Sales by Application (2019-2030)
5.1.1 Global Biosimilars of Rituximab Sales by Application (2019-2024)
5.1.2 Global Biosimilars of Rituximab Sales by Application (2025-2030)
5.1.3 Global Biosimilars of Rituximab Sales Market Share by Application (2019-2030)
5.2 Global Biosimilars of Rituximab Revenue by Application (2019-2030)
5.2.1 Global Biosimilars of Rituximab Revenue by Application (2019-2024)
5.2.2 Global Biosimilars of Rituximab Revenue by Application (2025-2030)
5.2.3 Global Biosimilars of Rituximab Revenue Market Share by Application (2019-2030)
5.3 Global Biosimilars of Rituximab Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Corporation Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Biosimilars of Rituximab Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Amgen Biosimilars of Rituximab Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 AryoGen Pharmed
6.2.1 AryoGen Pharmed Corporation Information
6.2.2 AryoGen Pharmed Description and Business Overview
6.2.3 AryoGen Pharmed Biosimilars of Rituximab Sales, Revenue and Gross Margin (2019-2024)
6.2.4 AryoGen Pharmed Biosimilars of Rituximab Product Portfolio
6.2.5 AryoGen Pharmed Recent Developments/Updates
6.3 Biocad
6.3.1 Biocad Corporation Information
6.3.2 Biocad Description and Business Overview
6.3.3 Biocad Biosimilars of Rituximab Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Biocad Biosimilars of Rituximab Product Portfolio
6.3.5 Biocad Recent Developments/Updates
6.4 Cadila Pharmaceuticals
6.4.1 Cadila Pharmaceuticals Corporation Information
6.4.2 Cadila Pharmaceuticals Description and Business Overview
6.4.3 Cadila Pharmaceuticals Biosimilars of Rituximab Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Cadila Pharmaceuticals Biosimilars of Rituximab Product Portfolio
6.4.5 Cadila Pharmaceuticals Recent Developments/Updates
6.5 Celltrion
6.5.1 Celltrion Corporation Information
6.5.2 Celltrion Description and Business Overview
6.5.3 Celltrion Biosimilars of Rituximab Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Celltrion Biosimilars of Rituximab Product Portfolio
6.5.5 Celltrion Recent Developments/Updates
6.6 Dr Reddy’s Laboratories
6.6.1 Dr Reddy’s Laboratories Corporation Information
6.6.2 Dr Reddy’s Laboratories Description and Business Overview
6.6.3 Dr Reddy’s Laboratories Biosimilars of Rituximab Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Dr Reddy’s Laboratories Biosimilars of Rituximab Product Portfolio
6.6.5 Dr Reddy’s Laboratories Recent Developments/Updates
6.7 Teva
6.6.1 Teva Corporation Information
6.6.2 Teva Description and Business Overview
6.6.3 Teva Biosimilars of Rituximab Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Teva Biosimilars of Rituximab Product Portfolio
6.7.5 Teva Recent Developments/Updates
6.8 Hetero Group
6.8.1 Hetero Group Corporation Information
6.8.2 Hetero Group Description and Business Overview
6.8.3 Hetero Group Biosimilars of Rituximab Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Hetero Group Biosimilars of Rituximab Product Portfolio
6.8.5 Hetero Group Recent Developments/Updates
6.9 Innovent Biologics
6.9.1 Innovent Biologics Corporation Information
6.9.2 Innovent Biologics Description and Business Overview
6.9.3 Innovent Biologics Biosimilars of Rituximab Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Innovent Biologics Biosimilars of Rituximab Product Portfolio
6.9.5 Innovent Biologics Recent Developments/Updates
6.10 Intas Biopharmaceuticals
6.10.1 Intas Biopharmaceuticals Corporation Information
6.10.2 Intas Biopharmaceuticals Description and Business Overview
6.10.3 Intas Biopharmaceuticals Biosimilars of Rituximab Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Intas Biopharmaceuticals Biosimilars of Rituximab Product Portfolio
6.10.5 Intas Biopharmaceuticals Recent Developments/Updates
6.11 Viatris
6.11.1 Viatris Corporation Information
6.11.2 Viatris Biosimilars of Rituximab Description and Business Overview
6.11.3 Viatris Biosimilars of Rituximab Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Viatris Biosimilars of Rituximab Product Portfolio
6.11.5 Viatris Recent Developments/Updates
6.12 Probiomed
6.12.1 Probiomed Corporation Information
6.12.2 Probiomed Biosimilars of Rituximab Description and Business Overview
6.12.3 Probiomed Biosimilars of Rituximab Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Probiomed Biosimilars of Rituximab Product Portfolio
6.12.5 Probiomed Recent Developments/Updates
6.13 TRPharma
6.13.1 TRPharma Corporation Information
6.13.2 TRPharma Biosimilars of Rituximab Description and Business Overview
6.13.3 TRPharma Biosimilars of Rituximab Sales, Revenue and Gross Margin (2019-2024)
6.13.4 TRPharma Biosimilars of Rituximab Product Portfolio
6.13.5 TRPharma Recent Developments/Updates
6.14 Zenotech Laboratories
6.14.1 Zenotech Laboratories Corporation Information
6.14.2 Zenotech Laboratories Biosimilars of Rituximab Description and Business Overview
6.14.3 Zenotech Laboratories Biosimilars of Rituximab Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Zenotech Laboratories Biosimilars of Rituximab Product Portfolio
6.14.5 Zenotech Laboratories Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Biosimilars of Rituximab Industry Chain Analysis
7.2 Biosimilars of Rituximab Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Biosimilars of Rituximab Production Mode & Process
7.4 Biosimilars of Rituximab Sales and Marketing
7.4.1 Biosimilars of Rituximab Sales Channels
7.4.2 Biosimilars of Rituximab Distributors
7.5 Biosimilars of Rituximab Customers
8 Biosimilars of Rituximab Market Dynamics
8.1 Biosimilars of Rituximab Industry Trends
8.2 Biosimilars of Rituximab Market Drivers
8.3 Biosimilars of Rituximab Market Challenges
8.4 Biosimilars of Rituximab Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Biosimilars of Rituximab Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Biosimilars of Rituximab Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Biosimilars of Rituximab Market Competitive Situation by Manufacturers in 2023
Table 4. Global Biosimilars of Rituximab Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Biosimilars of Rituximab Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Biosimilars of Rituximab Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Biosimilars of Rituximab Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Biosimilars of Rituximab Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Biosimilars of Rituximab, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Biosimilars of Rituximab, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Biosimilars of Rituximab, Product Type & Application
Table 12. Global Key Manufacturers of Biosimilars of Rituximab, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Biosimilars of Rituximab by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilars of Rituximab as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Biosimilars of Rituximab Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Biosimilars of Rituximab Sales by Region (2019-2024) & (K Units)
Table 18. Global Biosimilars of Rituximab Sales Market Share by Region (2019-2024)
Table 19. Global Biosimilars of Rituximab Sales by Region (2025-2030) & (K Units)
Table 20. Global Biosimilars of Rituximab Sales Market Share by Region (2025-2030)
Table 21. Global Biosimilars of Rituximab Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Biosimilars of Rituximab Revenue Market Share by Region (2019-2024)
Table 23. Global Biosimilars of Rituximab Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Biosimilars of Rituximab Revenue Market Share by Region (2025-2030)
Table 25. North America Biosimilars of Rituximab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Biosimilars of Rituximab Sales by Country (2019-2024) & (K Units)
Table 27. North America Biosimilars of Rituximab Sales by Country (2025-2030) & (K Units)
Table 28. North America Biosimilars of Rituximab Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Biosimilars of Rituximab Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Biosimilars of Rituximab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Biosimilars of Rituximab Sales by Country (2019-2024) & (K Units)
Table 32. Europe Biosimilars of Rituximab Sales by Country (2025-2030) & (K Units)
Table 33. Europe Biosimilars of Rituximab Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Biosimilars of Rituximab Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Biosimilars of Rituximab Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Biosimilars of Rituximab Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Biosimilars of Rituximab Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Biosimilars of Rituximab Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Biosimilars of Rituximab Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Biosimilars of Rituximab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Biosimilars of Rituximab Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Biosimilars of Rituximab Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Biosimilars of Rituximab Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Biosimilars of Rituximab Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Biosimilars of Rituximab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Biosimilars of Rituximab Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Biosimilars of Rituximab Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Biosimilars of Rituximab Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Biosimilars of Rituximab Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Biosimilars of Rituximab Sales (K Units) by Type (2019-2024)
Table 51. Global Biosimilars of Rituximab Sales (K Units) by Type (2025-2030)
Table 52. Global Biosimilars of Rituximab Sales Market Share by Type (2019-2024)
Table 53. Global Biosimilars of Rituximab Sales Market Share by Type (2025-2030)
Table 54. Global Biosimilars of Rituximab Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Biosimilars of Rituximab Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Biosimilars of Rituximab Revenue Market Share by Type (2019-2024)
Table 57. Global Biosimilars of Rituximab Revenue Market Share by Type (2025-2030)
Table 58. Global Biosimilars of Rituximab Price (US$/Unit) by Type (2019-2024)
Table 59. Global Biosimilars of Rituximab Price (US$/Unit) by Type (2025-2030)
Table 60. Global Biosimilars of Rituximab Sales (K Units) by Application (2019-2024)
Table 61. Global Biosimilars of Rituximab Sales (K Units) by Application (2025-2030)
Table 62. Global Biosimilars of Rituximab Sales Market Share by Application (2019-2024)
Table 63. Global Biosimilars of Rituximab Sales Market Share by Application (2025-2030)
Table 64. Global Biosimilars of Rituximab Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Biosimilars of Rituximab Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Biosimilars of Rituximab Revenue Market Share by Application (2019-2024)
Table 67. Global Biosimilars of Rituximab Revenue Market Share by Application (2025-2030)
Table 68. Global Biosimilars of Rituximab Price (US$/Unit) by Application (2019-2024)
Table 69. Global Biosimilars of Rituximab Price (US$/Unit) by Application (2025-2030)
Table 70. Amgen Corporation Information
Table 71. Amgen Description and Business Overview
Table 72. Amgen Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Amgen Biosimilars of Rituximab Product
Table 74. Amgen Recent Developments/Updates
Table 75. AryoGen Pharmed Corporation Information
Table 76. AryoGen Pharmed Description and Business Overview
Table 77. AryoGen Pharmed Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. AryoGen Pharmed Biosimilars of Rituximab Product
Table 79. AryoGen Pharmed Recent Developments/Updates
Table 80. Biocad Corporation Information
Table 81. Biocad Description and Business Overview
Table 82. Biocad Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Biocad Biosimilars of Rituximab Product
Table 84. Biocad Recent Developments/Updates
Table 85. Cadila Pharmaceuticals Corporation Information
Table 86. Cadila Pharmaceuticals Description and Business Overview
Table 87. Cadila Pharmaceuticals Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Cadila Pharmaceuticals Biosimilars of Rituximab Product
Table 89. Cadila Pharmaceuticals Recent Developments/Updates
Table 90. Celltrion Corporation Information
Table 91. Celltrion Description and Business Overview
Table 92. Celltrion Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Celltrion Biosimilars of Rituximab Product
Table 94. Celltrion Recent Developments/Updates
Table 95. Dr Reddy’s Laboratories Corporation Information
Table 96. Dr Reddy’s Laboratories Description and Business Overview
Table 97. Dr Reddy’s Laboratories Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Dr Reddy’s Laboratories Biosimilars of Rituximab Product
Table 99. Dr Reddy’s Laboratories Recent Developments/Updates
Table 100. Teva Corporation Information
Table 101. Teva Description and Business Overview
Table 102. Teva Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Teva Biosimilars of Rituximab Product
Table 104. Teva Recent Developments/Updates
Table 105. Hetero Group Corporation Information
Table 106. Hetero Group Description and Business Overview
Table 107. Hetero Group Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Hetero Group Biosimilars of Rituximab Product
Table 109. Hetero Group Recent Developments/Updates
Table 110. Innovent Biologics Corporation Information
Table 111. Innovent Biologics Description and Business Overview
Table 112. Innovent Biologics Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Innovent Biologics Biosimilars of Rituximab Product
Table 114. Innovent Biologics Recent Developments/Updates
Table 115. Intas Biopharmaceuticals Corporation Information
Table 116. Intas Biopharmaceuticals Description and Business Overview
Table 117. Intas Biopharmaceuticals Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Intas Biopharmaceuticals Biosimilars of Rituximab Product
Table 119. Intas Biopharmaceuticals Recent Developments/Updates
Table 120. Viatris Corporation Information
Table 121. Viatris Description and Business Overview
Table 122. Viatris Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Viatris Biosimilars of Rituximab Product
Table 124. Viatris Recent Developments/Updates
Table 125. Probiomed Corporation Information
Table 126. Probiomed Description and Business Overview
Table 127. Probiomed Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Probiomed Biosimilars of Rituximab Product
Table 129. Probiomed Recent Developments/Updates
Table 130. TRPharma Corporation Information
Table 131. TRPharma Description and Business Overview
Table 132. TRPharma Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. TRPharma Biosimilars of Rituximab Product
Table 134. TRPharma Recent Developments/Updates
Table 135. Zenotech Laboratories Corporation Information
Table 136. Zenotech Laboratories Description and Business Overview
Table 137. Zenotech Laboratories Biosimilars of Rituximab Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. Zenotech Laboratories Biosimilars of Rituximab Product
Table 139. Zenotech Laboratories Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Biosimilars of Rituximab Distributors List
Table 143. Biosimilars of Rituximab Customers List
Table 144. Biosimilars of Rituximab Market Trends
Table 145. Biosimilars of Rituximab Market Drivers
Table 146. Biosimilars of Rituximab Market Challenges
Table 147. Biosimilars of Rituximab Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Biosimilars of Rituximab
Figure 2. Global Biosimilars of Rituximab Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Biosimilars of Rituximab Market Share by Type in 2023 & 2030
Figure 4. 500mg Product Picture
Figure 5. 100mg Product Picture
Figure 6. Other Product Picture
Figure 7. Global Biosimilars of Rituximab Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Biosimilars of Rituximab Market Share by Application in 2023 & 2030
Figure 9. Hospital Pharmacy
Figure 10. Retail Pharmacy
Figure 11. Global Biosimilars of Rituximab Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Biosimilars of Rituximab Market Size (2019-2030) & (US$ Million)
Figure 13. Global Biosimilars of Rituximab Sales (2019-2030) & (K Units)
Figure 14. Global Biosimilars of Rituximab Average Price (US$/Unit) & (2019-2030)
Figure 15. Biosimilars of Rituximab Report Years Considered
Figure 16. Biosimilars of Rituximab Sales Share by Manufacturers in 2023
Figure 17. Global Biosimilars of Rituximab Revenue Share by Manufacturers in 2023
Figure 18. The Global 5 and 10 Largest Biosimilars of Rituximab Players: Market Share by Revenue in 2023
Figure 19. Biosimilars of Rituximab Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 20. Global Biosimilars of Rituximab Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Biosimilars of Rituximab Sales Market Share by Country (2019-2030)
Figure 22. North America Biosimilars of Rituximab Revenue Market Share by Country (2019-2030)
Figure 23. United States Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Biosimilars of Rituximab Sales Market Share by Country (2019-2030)
Figure 26. Europe Biosimilars of Rituximab Revenue Market Share by Country (2019-2030)
Figure 27. Germany Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Russia Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Biosimilars of Rituximab Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Biosimilars of Rituximab Revenue Market Share by Region (2019-2030)
Figure 34. China Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Australia Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. China Taiwan Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Indonesia Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Thailand Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Malaysia Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Latin America Biosimilars of Rituximab Sales Market Share by Country (2019-2030)
Figure 44. Latin America Biosimilars of Rituximab Revenue Market Share by Country (2019-2030)
Figure 45. Mexico Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Brazil Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Argentina Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Biosimilars of Rituximab Sales Market Share by Country (2019-2030)
Figure 49. Middle East & Africa Biosimilars of Rituximab Revenue Market Share by Country (2019-2030)
Figure 50. Turkey Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. UAE Biosimilars of Rituximab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Global Sales Market Share of Biosimilars of Rituximab by Type (2019-2030)
Figure 54. Global Revenue Market Share of Biosimilars of Rituximab by Type (2019-2030)
Figure 55. Global Biosimilars of Rituximab Price (US$/Unit) by Type (2019-2030)
Figure 56. Global Sales Market Share of Biosimilars of Rituximab by Application (2019-2030)
Figure 57. Global Revenue Market Share of Biosimilars of Rituximab by Application (2019-2030)
Figure 58. Global Biosimilars of Rituximab Price (US$/Unit) by Application (2019-2030)
Figure 59. Biosimilars of Rituximab Value Chain
Figure 60. Biosimilars of Rituximab Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
